Vitamin D Research
back to research menu
Benign Prostatic Hyperplasia
- Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2009 Jun 8.
- Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs. 2009 Jun;12(6):381–93.
- The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009 Apr 1;69(5):480–93.
- Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. Coll Antropol. 2008 Dec;32(4):1195–202.
- Circulating 25-hydroxyvitamin D concentration in German cancer patients. Oncol Rep. 2008 Dec;20(6):1539–43.
- Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008 Apr 15;167(8):925–34.
- Pathophysiology and therapy of benign prostatic hyperplasia. Wien Klin Wochenschr. 2008;120(13–14):390–401. Review.
- LUTS treatment: future treatment options. Neurourol Urodyn. 2007 Oct;26(6 Suppl):934–47. Review.
- Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):689–93.
- BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007 Feb 15;67(3):234–47.
- Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer. 2006 Oct 15;119(8):1902–7.
- Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol. 2006 Sep;50(3):549–54.
- Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J Endocrinol Invest. 2006 Jul–Aug;29(7):665–74. Review.
- The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006 Jun;132(6):408–16.
- Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urology. 2006 Feb;67(2):300–5.
- Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973–81.
- Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J. 2004 Apr;25(4):447–51.
- Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203–8.
- Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology. 2003 Jun;61(6):1261–5.
- CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003 Mar 24;88(6):928–32.
- Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). Int J Oncol. 2003 Jan;22(1):5–13. Review.
- Des (1–3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol. 2002 Dec 30;198(1–2):69–75.
- 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 2002 Jun;81(2):135–40.
- Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate. 2002 Apr 1;51(1):30–4.
- Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int. 2002;68(4):226–31.
- Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001 Apr 1;61(7):2852–6.
- Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology. 2001 Mar;57(3):567–72.
- Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol. 2000 Feb;37(2):234–8.
- Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000 Jan 15;60(2):305–8.
- A medical hypothesis: phosphorus balance and prostate cancer. Cancer Invest. 2000;18(7):664–9. Review.
- Molecular characterisation and racial distribution of androgen and vitamin D receptor polymorphisms in patients with prostate cancer, benign prostatic hyperplasia and age-matched healthy controls. Prostate Cancer Prostatic Dis. 1999 Nov;2(S3):S30.
- Phosphorus balance and prostate cancer. Indian J Exp Biol. 1999 Jul;37(7):623–6. Review.
- Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):391–5.
- Parathyroid hormone—related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate. 1996 Jul;29(1):20–9.
- Cellular biology of prostatic growth factors. Prostate Suppl. 1996;6:74–8. Review.
- Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993 Sep–Oct;2(5):467–72.
- Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab. 1993 Feb;76(2):288–90.
- Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf). 1992 Nov;37(5):432–6.
- Genetic markers in carcinoma of the prostate. Eur Urol. 1984;10(5):315–6.
back to research menu